"Immunotherapy, Adoptive" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Form of adoptive transfer where cells with antitumor activity are transferred to the tumor-bearing host in order to mediate tumor regression. The lymphoid cells commonly used are lymphokine-activated killer (LAK) cells and tumor-infiltrating lymphocytes (TIL). This is usually considered a form of passive immunotherapy. (From DeVita, et al., Cancer, 1993, pp.305-7, 314)
| Descriptor ID |
D016219
|
| MeSH Number(s) |
E02.095.465.425.400.330.050.400 E05.478.550.520.050.400
|
| Concept/Terms |
Immunotherapy, Adoptive- Immunotherapy, Adoptive
- Immunotherapy, Adoptive Cellular
- Adoptive Immunotherapy
- Adoptive Immunotherapies
- Immunotherapies, Adoptive
- Cellular Immunotherapy, Adoptive
- Adoptive Cellular Immunotherapies
- Cellular Immunotherapies, Adoptive
- Immunotherapies, Adoptive Cellular
- Adoptive Cellular Immunotherapy
|
Below are MeSH descriptors whose meaning is more general than "Immunotherapy, Adoptive".
Below are MeSH descriptors whose meaning is more specific than "Immunotherapy, Adoptive".
This graph shows the total number of publications written about "Immunotherapy, Adoptive" by people in this website by year, and whether "Immunotherapy, Adoptive" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 2 | 1 | 3 |
| 1997 | 1 | 0 | 1 |
| 1998 | 8 | 2 | 10 |
| 2000 | 1 | 1 | 2 |
| 2001 | 5 | 1 | 6 |
| 2002 | 3 | 5 | 8 |
| 2003 | 3 | 3 | 6 |
| 2004 | 6 | 0 | 6 |
| 2005 | 4 | 0 | 4 |
| 2006 | 8 | 2 | 10 |
| 2007 | 6 | 2 | 8 |
| 2008 | 4 | 1 | 5 |
| 2009 | 3 | 1 | 4 |
| 2010 | 7 | 2 | 9 |
| 2011 | 11 | 0 | 11 |
| 2012 | 6 | 4 | 10 |
| 2013 | 5 | 4 | 9 |
| 2014 | 9 | 4 | 13 |
| 2015 | 6 | 0 | 6 |
| 2016 | 2 | 7 | 9 |
| 2017 | 13 | 2 | 15 |
| 2018 | 13 | 4 | 17 |
| 2019 | 13 | 8 | 21 |
| 2020 | 18 | 8 | 26 |
| 2021 | 9 | 8 | 17 |
| 2022 | 6 | 22 | 28 |
| 2023 | 7 | 23 | 30 |
| 2024 | 29 | 10 | 39 |
| 2025 | 40 | 6 | 46 |
| 2026 | 23 | 1 | 24 |
To return to the timeline,
click here.
Below are the most recent publications written about "Immunotherapy, Adoptive" by people in Profiles.
-
Injectable bioinstructive microfoam for rapid bedside/in vivo programming of CAR-T cells. Mol Ther. 2026 Oct 07; 34(10):5818-5830.
-
Enhancing CAR- and TCR-mediated targeting of cancer via an immune synapse-stabilizing receptor. Nat Commun. 2026 Feb 04; 17(1):1349.
-
Lung tumouroids as a testing platform for precision CAR T cell therapy. Nat Biomed Eng. 2026 Apr; 10(4):815-831.
-
IL-18 metabolically reprograms CAR-expressing natural killer T cells and enhances their antitumor activity. Mol Ther. 2026 Apr 01; 34(4):2154-2174.
-
Impact of Chimeric Antigen Receptor T-Cell Therapy on Health Utilities of Patients Diagnosed with Diffuse Large B-Cell Lymphoma in Canada. Transplant Cell Ther. 2026 Mar; 32(3):360.e1-360.e12.
-
Endoglin-Directed CAR T Cells Comprehensively Target Tumors in Advanced Sarcomas. Cancer Immunol Res. 2025 Oct 01; 13(10):1591-1608.
-
TIGIT Affects CAR NK-cell Effector Function in the Solid Tumor Microenvironment by Modulating Immune Synapse Strength. Cancer Immunol Res. 2025 Oct 01; 13(10):1576-1590.
-
Outcomes of brexucabtagene autoleucel in patients with relapsed/refractory acute lymphoblastic leukemia with CNS involvement. Blood Adv. 2025 Aug 26; 9(16):4081-4089.
-
Constitutive IL-7 signaling promotes CAR-NK cell survival in the solid tumor microenvironment but impairs tumor control. J Immunother Cancer. 2025 Jul 23; 13(7).
-
Large B cell lymphoma microenvironment archetype profiles. Cancer Cell. 2025 Jul 14; 43(7):1347-1364.e13.